A supervised human trial found oral psilocin and psilocybin produced nearly indistinguishable effects, while oral psilocin caused fewer adverse side effects and sublingual psilocin was milder and shorter-lived.

The first direct human comparison since the 1960s examined psilocin and psilocybin across onset, intensity, duration and deep psychological effects. Oral psilocin had a lower overall burden of mostly mild adverse effects, while sublingual psilocin was well tolerated but produced milder, shorter-lived effects with less systemic exposure.